Nebivolol hydrochloride

Modify Date: 2024-01-02 10:22:42

Nebivolol hydrochloride structure	Common Name	Nebivolol hydrochloride
	CAS Number	152520-56-4	Molecular Weight	441.896
	Density	N/A	Boiling Point	600.5ºC at 760 mmHg
	Molecular Formula	C₂₂H₂₆ClF₂NO₄	Melting Point	220-222ºC
	MSDS	Chinese USA	Flash Point	316.9ºC
	Symbol	GHS07, GHS09	Signal Word	Warning

Use of Nebivolol hydrochloride

Nebivolol hydrochloride selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.Target: β1- adrenergic receptorNebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner. Nebivolol treatment for 7 days causes significant reduction in cell growth of haCSMCs with IC50 of 6.1 μM, and inhibits accelerated haCSMC proliferation stimulated by growth factors PDGF-BB, bFGF, and TGFβ with IC50 values of 6.8 μM, 6.4 μM and 7.7 μM, repectively. Nebivolol treatment (10-5 M) of haCSMCs for 48 hours induces a moderate apoptosis of 23% and a decrease from 16% to 5% in the number of cells in S-phase. During Nebivolol incubation, NO formation of HaCEs increases, while endothelin-1 transcription and secretion are suppressed.Administratiion of Nebivolol (initially by iv within 10 minutes of reperfusion and then orally) to rats with myocardial infarction (MI) reduces myocardial apoptosis, which is mediated by regulation of NO . Nebivolol, significantly, prevents left ventricular (LV) pressure changes, reduces total and regional apoptotic cardiomyocytes. Nebivolol treatment lowers mean blood pressure (MBP) in rats with MI slightly, but not significantly.

Name	Nebivolol Hydrochloride
Synonym	More Synonyms

Description	Nebivolol hydrochloride selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.Target: β1- adrenergic receptorNebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner. Nebivolol treatment for 7 days causes significant reduction in cell growth of haCSMCs with IC50 of 6.1 μM, and inhibits accelerated haCSMC proliferation stimulated by growth factors PDGF-BB, bFGF, and TGFβ with IC50 values of 6.8 μM, 6.4 μM and 7.7 μM, repectively. Nebivolol treatment (10-5 M) of haCSMCs for 48 hours induces a moderate apoptosis of 23% and a decrease from 16% to 5% in the number of cells in S-phase. During Nebivolol incubation, NO formation of HaCEs increases, while endothelin-1 transcription and secretion are suppressed.Administratiion of Nebivolol (initially by iv within 10 minutes of reperfusion and then orally) to rats with myocardial infarction (MI) reduces myocardial apoptosis, which is mediated by regulation of NO . Nebivolol, significantly, prevents left ventricular (LV) pressure changes, reduces total and regional apoptotic cardiomyocytes. Nebivolol treatment lowers mean blood pressure (MBP) in rats with MI slightly, but not significantly.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Cardiovascular Disease
References	[1]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9. [2]. Mercanoglu G, et al. The effects of nebivolol on apoptosis in a rat infarct model. Circ J. 2008 Apr;72(4):660-70.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor

Research Areas >> Cardiovascular Disease

References

[1]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9.

[2]. Mercanoglu G, et al. The effects of nebivolol on apoptosis in a rat infarct model. Circ J. 2008 Apr;72(4):660-70.

Boiling Point	600.5ºC at 760 mmHg
Melting Point	220-222ºC
Molecular Formula	C₂₂H₂₆ClF₂NO₄
Molecular Weight	441.896
Flash Point	316.9ºC
Exact Mass	441.151855
PSA	70.95000
LogP	3.55650
Vapour Pressure	2.88E-15mmHg at 25°C
Storage condition	Desiccate at RT
Water Solubility	DMSO: ≥20mg/mL

Nebivolol hydrochloride MSDS(Chinese)

Symbol	GHS07, GHS09
Signal Word	Warning
Hazard Statements	H302-H410
Precautionary Statements	P273-P501
Hazard Codes	Xn,N
Risk Phrases	22-50/53
Safety Phrases	60-61
RIDADR	3077
HS Code	2932999099

HS Code	2932999099
Summary	2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Design, development and permeation studies of nebivolol hydrochloride from novel matrix type transdermal patches.

Adv. Biomed. Res. 2 , 62, (2013)

Nebivolol hydrochloride is a third generation β-blocker with highly selective β1-receptor antagonist with antihypertensive properties having plasma half life of 10 h and 12% oral bioavailability. The ...

Simultaneous estimation of amlodipine besylate and nebivolol hydrochloride in tablet dosage forms by reverse phase-high-performance liquid chromatographic using ultraviolet detection.

Pharm. Methods 2 , 9-14, (2013)

The present study aimed to develop and validate the simultaneous estimation of amlodipine and nebivolol in tablet dosage forms.An isocratic reversed phase high-performance liquid chromatographic (HPLC...

Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.

FASEB J. 25 , 4486-97, (2011)

β-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which th...

2H-1-Benzopyran-2-ethanaminium, 6-fluoro-N-[(2R)-2-[(2R)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl]-2-hydroxyethyl]-3,4-dihydro-β-hydroxy-, chloride, (βR,2S)- (1:1)

(S,R,R,R)-nebivolol hydrochloride

(2R)-2-[(2R)-6-Fluoro-3,4-dihydro-2H-chromen-2-yl]-N-{(2R)-2-[(2S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-hydroxyethyl}-2-hydroxyethanaminium chloride

Nebivolol hydrochloride